ArticleJournal of neural transmission (Vienna, Austria : 1996)2011
Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Pooled it
- The correlates of hyperechogenicity of the substantia nigra in subjects at risk of dementia with Lewy bodies.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Substantia nigra hyperechogenicity and brain ventricular size as biomarkers of early dementia with Lewy bodies.Alzheimer's research & therapy · 2024Article
- Psychomotor Slowing in Schizophrenia: Implications for Endophenotype and Biomarker Development.Biomarkers in neuropsychiatry · 2020Article
- Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity.Scientific reports · 2017Article
- Parkinsonism in a pair of monozygotic CADASIL twins sharing the R1006C mutation: a transcranial sonography study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Article
- Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.Journal of neural transmission (Vienna, Austria : 1996) · 2015Article
- Substantia nigra echogenicity in hereditary ataxias with and without nigrostriatal pathology: a pilot study.Cerebellum (London, England) · 2015Article
- Sex and laterality differences in parkinsonian impairment and transcranial ultrasound in never-treated schizophrenics and their first degree relatives in an Andean population.Schizophrenia research · 2015Article
- Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.Focus (American Psychiatric Publishing) · 2015Article
- Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.Journal of neural transmission (Vienna, Austria : 1996) · 2012Review
- Specificity of transcranial sonography in parkinson spectrum disorders in comparison to degenerative cognitive syndromes.BMC neurology · 2012Article
- [The presymptomatic stage of neurodegenerative disorders].Der Nervenarzt · 2011Review
- Substantia Nigra Echogenicity Predicts Response to Drug Withdrawal in Suspected Drug-Induced Parkinsonism.Movement disorders clinical practiceArticle
Corrections and comments
- Commented on by
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As there is increasing evidence that the neurodegenerative process in Parkinson's disease (PD) starts years to decades before clinical symptoms allow diagnosis, markers for the identification of subjects at risk are eagerly sought after in order to allow an earlier, disease modulating or even neuroprotective therapy. In recent years, transcranial sonography (TCS) has evolved as a useful instrument in the differential diagnosis and also very early diagnosis of PD. The typical hallmark for PD, hyperechogenicity at the anatomical site of the substantia nigra (SN), can also be found in about 10% of healthy subjects. There is accumulating evidence that SN hyperechogenicity discloses a vulnerability of the nigrostriatal system in at least some of these persons. Moreover, an association of the ultrasound sign with a number of risk and premotor markers has been shown. However, the most striking argument for a relevance of SN hyperechogenicity in healthy subjects can be derived from the observation that some initially healthy subjects with SN hyperechogenicity developed PD in the long run, an observation which has led to longitudinal studies on the predictive value of the ultrasound sign for the development of PD. A first follow up after 3 years of a large cohort of at baseline extrapyramidally healthy individuals revealed a relative risk for incident PD 17.37 times higher in subjects with SN hyperechogenicity at baseline compared to those without this echomarker. Taken together, there is encouraging evidence to implement TCS in a screening battery to identify subjects at risk for the development of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.